Aliases & Classifications for Muscle Cancer

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer 12 54 15 17
Myosarcoma 12 54 44 71
Malignant Neoplasm of Muscle 12 71
Malignant Tumor of the Muscle 12
Malignant Tumor of Muscle 12
Myomatous Neoplasm 71
Muscle Neoplasms 44

Classifications:



External Ids:

Disease Ontology 12 DOID:4045
NCIt 50 C4883
SNOMED-CT 67 20667008 93913006
ICD10 32 C49
UMLS 71 C0027095 C0282606 C0684743

Summaries for Muscle Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in muscle.

MalaCards based summary : Muscle Cancer, also known as myosarcoma, is related to myoma and leiomyosarcoma, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are Transcriptional misregulation in cancer and C-MYB transcription factor network. The drugs Pembrolizumab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include muscle, liver and uterus, and related phenotypes are integument and muscle

Wikipedia : 74 A soft-tissue sarcoma (STS) is a malignant tumour, a type of cancer, that develops in soft tissue. A... more...

Related Diseases for Muscle Cancer

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 342)
# Related Disease Score Top Affiliating Genes
1 myoma 32.3 TP53 KIT CD34 CALD1
2 leiomyosarcoma 31.9 TP53 SERPINA3 MYOG KIT DES
3 rhabdomyosarcoma 31.7 TP53 PAX7 PAX3 MYOG MYOD1 KIT
4 skeletal muscle cancer 31.7 TP53 TFE3 SERPINA3 RHD PAX7 PAX3
5 cutaneous leiomyosarcoma 30.8 DES CD34 CALD1
6 sarcoma 30.7 TP53 TFE3 MYOG KIT EWSR1 ASPSCR1
7 spindle cell sarcoma 30.7 SERPINA3 MYOG KIT EWSR1 DES CD34
8 smooth muscle tumor 30.6 SERPINA3 KIT DES CD34 CALD1
9 intravenous leiomyomatosis 30.6 DES CD34 CALD1
10 botryoid rhabdomyosarcoma 30.6 PAX3 MYOG MYOD1 DES
11 infantile myofibromatosis 30.6 DES CD34 CALD1
12 fibrosarcoma 30.5 TP53 KIT EWSR1 DES
13 hemangiopericytoma, malignant 30.4 SERPINA3 MYOG KIT DES CD34 CALD1
14 angiomyolipoma 30.3 TFE3 KIT DES
15 carcinosarcoma 30.3 TP53 KIT DES
16 vulvar leiomyoma 30.3 CD34 CALD1
17 bizarre leiomyoma 30.3 TP53 CALD1
18 bladder leiomyoma 30.2 MYOD1 KIT EWSR1 CD34 CALD1
19 embryonal rhabdomyosarcoma 30.2 TP53 PAX7 PAX3 MYOG MYOD1 FOXO1
20 endometrial stromal sarcoma 30.2 TP53 KIT EWSR1 DES CALD1
21 mesenchymal cell neoplasm 30.0 TP53 TFE3 SERPINA3 MYOG MIR199A1 KIT
22 striated muscle rhabdoid tumor 10.8
23 central nervous system rhabdomyosarcoma 10.6 PAX3 FOXO1
24 ovarian fibrothecoma 10.6 KIT DES
25 lung combined type small cell carcinoma 10.6 MYOG CALD1
26 urethra leiomyoma 10.6 KIT CALD1
27 fibroma 10.6 SERPINA3 DES CD34
28 congenital epulis 10.6 SERPINA3 DES
29 spinal cord sarcoma 10.6 KIT CD34
30 gallbladder sarcoma 10.6 MYOG MYOD1 DES
31 extraskeletal chondroma 10.6 SERPINA3 EWSR1
32 malignant triton tumor 10.6 MYOG MYOD1 DES
33 intravascular angioleiomyoma 10.6 CD34 CALD1
34 skeletal muscle neoplasm 10.6 RHD MYOG MYOD1
35 gallbladder leiomyoma 10.6 KIT CD34
36 breast myofibroblastoma 10.6 CD34 CALD1
37 scrotum neoplasm 10.5 SERPINA3 MYOG
38 pineal region teratoma 10.5 MYOG MYOD1 KIT
39 gas gangrene 10.5 SERPINA3 MYOG MYOD1
40 small intestine leiomyosarcoma 10.5 KIT CD34
41 extraosseous ewing sarcoma 10.5 MYOG MYOD1 EWSR1
42 spermatic cord cancer 10.5 MYOD1 CD34
43 neuronal intestinal dysplasia, type b 10.5 KIT CD34
44 malignant epithelioid hemangioendothelioma 10.5 TFE3 SERPINA3
45 glomangiomyoma 10.5 CD34 CALD1
46 glomangioma 10.5 DES CD34 CALD1
47 adult cystic nephroma 10.5 KIT DES
48 prostate rhabdomyosarcoma 10.5 MYOG MYOD1
49 ectomesenchymoma 10.5 PAX3 MYOG FOXO1 DES
50 extracranial neuroblastoma 10.5 MYOG EWSR1

Graphical network of the top 20 diseases related to Muscle Cancer:



Diseases related to Muscle Cancer

Symptoms & Phenotypes for Muscle Cancer

UMLS symptoms related to Muscle Cancer:


muscle weakness, myoclonus, myalgia, torticollis, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Muscle Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.91 CD34 FOXO1 KIT MYOG PAX3 PAX7
2 muscle MP:0005369 9.76 DES FOXO1 KIT MYOD1 MYOG PAX3
3 neoplasm MP:0002006 9.5 CD34 FOXO1 KIT MYOD1 PAX3 PAX7
4 no phenotypic analysis MP:0003012 9.17 FOXO1 KIT MYOD1 MYOG PAX3 PAX7

Drugs & Therapeutics for Muscle Cancer

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pembrolizumab Approved Phase 3 1374853-91-4
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4 Immunosuppressive Agents Phase 3
5 Immunologic Factors Phase 3
6 Antineoplastic Agents, Immunological Phase 3
7 Anti-Infective Agents Phase 3
8 Antimetabolites Phase 3
9 Antiviral Agents Phase 3
10
Melphalan Approved Phase 2 148-82-3 4053 460612
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Mesna Approved, Investigational Phase 2 3375-50-6 598
13
Ifosfamide Approved Phase 2 3778-73-2 3690
14 Alkylating Agents Phase 2
15
Liposomal doxorubicin Phase 2 31703
16
Isophosphamide mustard Phase 2 100427
17 Antibiotics, Antitubercular Phase 1
18 Liver Extracts Phase 1
19 Anti-Bacterial Agents Phase 1
20 Cola Phase 1
21 Analgesics, Non-Narcotic Phase 1
22 Interleukin-2 Phase 1
23 Vaccines Phase 1
24 Analgesics Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Cisplatin-Ineligible Participants With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) Recruiting NCT03924895 Phase 3 Pembrolizumab;Enfortumab Vedotin
2 A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866) Recruiting NCT03924856 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
3 Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity Completed NCT00019968 Phase 2 melphalan;tumor necrosis factor
4 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Active, not recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
5 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
6 Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
7 Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study Completed NCT02380651

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Genetic Tests for Muscle Cancer

Anatomical Context for Muscle Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Muscle Cancer:

19
Muscle

MalaCards organs/tissues related to Muscle Cancer:

40
Liver, Uterus, Skeletal Muscle, Skin, Colon, Kidney, Prostate

Publications for Muscle Cancer

Articles related to Muscle Cancer:

(show top 50) (show all 134)
# Title Authors PMID Year
1
New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. 61 54
16140913 2005
2
Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract. 54 61
11473460 2001
3
Tenosynovial giant cell tumors: evidence for a desmin-positive dendritic cell subpopulation. 61 54
9796719 1998
4
From Bench to Bedside in Tongue Muscle Cancer Invasion and Back again: Gross Anatomy, Microanatomy, Surgical Treatments and Basic Research. 61
32932638 2020
5
Opposing effects of 25-hydroxy- and 1α,25-dihydroxy-vitamin D3 on pro-cachectic cytokine-and cancer conditioned medium-induced atrophy in C2C12 myotubes. 61
30834670 2019
6
Diagnostic immunohistochemistry for canine cutaneous round cell tumours - retrospective analysis of 60 cases. 61
31553052 2019
7
Effect of Ninjin'yoeito on the Loss of Skeletal Muscle Function in Cancer-Bearing Mice. 61
30555329 2018
8
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. 61
28250653 2017
9
Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. 61
26071135 2015
10
Differential cytotoxic properties of Helleborus niger L. on tumour and immunocompetent cells. 61
25446603 2015
11
Application experience of intraoperative neuromonitoring in thyroidectomy. 61
26885214 2015
12
YAPping about differentiation therapy in muscle cancer. 61
25117705 2014
13
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma. 61
23665679 2014
14
The not-so-skinny on muscle cancer. 61
23079652 2012
15
Mouse models of sarcomas: critical tools in our understanding of the pathobiology. 61
23036318 2012
16
AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. 61
22333587 2012
17
Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. 61
21423212 2011
18
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. 61
21493592 2011
19
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. 61
21447712 2011
20
Chandipura virus growth kinetics in vertebrate cell lines, insect cell lines & embryonated eggs. 61
20716815 2010
21
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. 61
20193046 2010
22
A novel POK family transcription factor, ZBTB5, represses transcription of p21CIP1 gene. 61
19491398 2009
23
Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. 61
19339268 2009
24
MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. 61
19299559 2009
25
Correction of dystrophia myotonica type 1 pre-mRNA transcripts by artificial trans-splicing. 61
18923454 2009
26
PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. 61
18679424 2008
27
[Non-epithelial tumors of the large intestine]. 61
19172837 2008
28
A new model for muscle cancer. 61
17585343 2007
29
Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. 61
16964289 2007
30
The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. 61
16488997 2006
31
Malignancy-induced autoimmunity to MUC1: initial antibody characterization. 61
16316451 2005
32
Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. 61
15981282 2005
33
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. 61
15489287 2004
34
New chromanone acids with antibacterial activity from Calophyllum brasiliense. 61
15104480 2004
35
Cytotoxic effects of some animal and vegetable extracts and some chemicals on liver and colon carcinoma and myosarcoma. 61
14968209 2004
36
Synergistic effects of adenosine A1 and P2Y receptor stimulation on calcium mobilization and PKC translocation in DDT1 MF-2 cells. 61
12825834 2003
37
In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. 61
12447687 2002
38
Prognostic factors and survival in late adolescent and adult patients with small round cell tumors. 61
12151977 2002
39
Successful resection of a re-occurred pulmonary myosarcoma in a patient with turner syndrome mosaic. 61
18521351 2002
40
Modification of hemostatic status improves antitumor efficiency of photodynamic therapy. 61
11427917 2001
41
[Primitive leiomyosarcoma of the right atrium presenting with a pulmonary embolism]. 61
10830098 2000
42
Aggressive congenital fibromatosis of the small intestine in the newborn. Report of a case and review of the literature. 61
10661858 1999
43
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. 61
9615866 1998
44
[Bladder leiomyosarcoma. Report of a new case]. 61
9065095 1996
45
Retrorectal tumors complicating pregnancy. Report of two cases. 61
8831537 1996
46
[Antithrombogenic activity of blood vessel walls in the pathogenesis of metastasis in tumor-bearing animals]. 61
8966053 1996
47
Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity. 61
7737913 1995
48
Radioimmunoscintigraphy using [111In]antimyosin Fab fragments for the diagnosis and follow-up of rhabdomyosarcoma. 61
8297646 1993
49
Myofibromatosis-like hemangiopericytoma metastasizing as differentiated vascular smooth-muscle and myosarcoma. Myopericytes as a subset of "myofibroblasts". 61
1463097 1992
50
Angiomatoid "malignant fibrous histiocytoma": an immunohistochemical study indicative of myoid differentiation. 61
1650754 1991

Variations for Muscle Cancer

Cosmic variations for Muscle Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM95516578 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
2 COSM95520543 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
3 COSM95523461 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
4 COSM95526780 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 3
5 COSM87494413 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 3

Expression for Muscle Cancer

Search GEO for disease gene expression data for Muscle Cancer.

Pathways for Muscle Cancer

GO Terms for Muscle Cancer

Cellular components related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin GO:0000785 9.17 TP53 TFE3 PAX7 PAX3 MYOG MYOD1

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 9.92 TP53 TFE3 PAX7 PAX3 MYOG MYOD1
2 gene silencing by miRNA GO:0035195 9.83 MIR9-1 MIR675 MIR378A MIR199A1 MIR183
3 positive regulation of transcription, DNA-templated GO:0045893 9.73 TP53 TFE3 PAX3 MYOG MYOD1 FOXO1
4 regulation of transcription, DNA-templated GO:0006355 9.56 TP53 TFE3 PAX7 PAX3 MYOG MYOD1
5 myotube differentiation GO:0014902 9.4 MYOG MYOD1
6 positive regulation of skeletal muscle fiber development GO:0048743 9.37 MYOG MYOD1
7 muscle cell fate commitment GO:0042693 9.16 MYOG MYOD1
8 muscle organ development GO:0007517 8.92 PAX7 PAX3 MYOG MYOD1

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.95 TP53 TFE3 PAX7 PAX3 MYOG MYOD1
2 sequence-specific double-stranded DNA binding GO:1990837 9.83 TFE3 PAX7 PAX3 MYOG MYOD1
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 TP53 TFE3 PAX7 PAX3 MYOG MYOD1
4 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.72 TP53 TFE3 MYOG MYOD1 FOXO1
5 proximal promoter sequence-specific DNA binding GO:0000987 9.54 TP53 MYOG MYOD1
6 mRNA 3'-UTR binding GO:0003730 9.46 TP53 MIR9-1 MIR675 MIR183
7 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.35 MIR9-1 MIR675 MIR378A MIR199A1 MIR183
8 DNA-binding transcription factor activity GO:0003700 9.17 TP53 TFE3 PAX7 PAX3 MYOG MYOD1

Sources for Muscle Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....